125 related articles for article (PubMed ID: 34282313)
1. Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.
Imoto M; Fujimaki T; Saito S; Tashiro E
J Antibiot (Tokyo); 2021 Oct; 74(10):706-716. PubMed ID: 34282313
[TBL] [Abstract][Full Text] [Related]
2. Antarlides F-H, new members of the antarlide family produced by Streptomyces sp. BB47.
Saito S; Fujimaki T; Panbangred W; Sawa R; Igarashi Y; Imoto M
J Antibiot (Tokyo); 2017 May; 70(5):595-600. PubMed ID: 28174422
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
4. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
5. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
[TBL] [Abstract][Full Text] [Related]
6. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
[TBL] [Abstract][Full Text] [Related]
8. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
9. Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy.
Saito S; Fujimaki T; Panbangred W; Igarashi Y; Imoto M
Angew Chem Int Ed Engl; 2016 Feb; 55(8):2728-32. PubMed ID: 26805525
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
12. Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
J Med Chem; 2021 Aug; 64(15):11045-11062. PubMed ID: 34269581
[TBL] [Abstract][Full Text] [Related]
13. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
[TBL] [Abstract][Full Text] [Related]
16. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
17. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
